Francesco Bianco1, Silvia De Franciscis2, Andrea Belli2, Maria Di Lena2, Antonio Avallone3, Maria Antonia Bianco4, Sabato Di Marzo5, Letizia Gigli6, Gianluca Rotondano4, Silvana Russo Spena6, Fabiana Tatangelo7, Alfonso Tempesta8, Giovanni Maria Romano2. 1. Department of Surgical Oncology, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale" - IRCCS, Via M. Semmola, 80131, Naples, Italy. bianco.bar@tin.it. 2. Department of Surgical Oncology, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale" - IRCCS, Via M. Semmola, 80131, Naples, Italy. 3. Department of Medical Oncology, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale" - IRCCS, Naples, Italy. 4. Gastroenterology and Digestive Endoscopy, Maresca Hospital, Torre Del Greco, Italy. 5. Gastroenterology and Digestive Endoscopy, Apicella Hospital, Pollena Trocchia, Italy. 6. Epidemiology and Prevention Unit, ASL NA3sud, Naples, Italy. 7. Department of Pathology, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale" - IRCCS, Naples, Italy. 8. Department of Endoscopy, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione Giovanni Pascale" - IRCCS, Naples, Italy.
Abstract
PURPOSE: From 2011 to 2013 in the area of the Naples 3 public health district (ASL-NA3), a colorectal cancer screening program (CCSP) was developed. In order to stress the need of quality assurance procedures for surgery and pathology, a third level oncologic pathway was added and set up at a referral colorectal cancer center (RC). Lymph nodal (LN) harvesting, as a process indicator, and nodal positivity were adopted for an interim analysis. METHODS: The program was implemented by a series of audit meetings and a double type of multidisciplinary team (MDT): "horizontal" and "vertical." Three hundred and forty colorectal cancer (CRC) patients underwent surgery: 119 chose to be operated at the RC (Gr In), 65 were operated at 22 district hospitals (DH) (Gr Out), and 156 symptomatic not screened patients were operated at the RC (Gr Sym). RESULTS: Statistical analysis revealed differences between Gr In and Gr Out colon groups both for LN harvesting (median of 26 and 11, respectively, P = 0.0001), and for nodal positivity after the first screening round (34.78 and 19.45%, respectively, P = 0.0169). Results were all the more significant in a subset analysis on early T stage colon subgroups (In vs Out) both for LN harvesting (P < 0.0001) and nodal positivity (P < 0.0001). CONCLUSION: xSignificant differences between RC and DHs were found, particularly for early-stage CRC patients. LN harvesting should be considered as a surrogate marker of quality assurance for at least screening hospitals for "minimum best" standard of care. This should lead to set up a third level in any CCSP.
PURPOSE: From 2011 to 2013 in the area of the Naples 3 public health district (ASL-NA3), a colorectal cancer screening program (CCSP) was developed. In order to stress the need of quality assurance procedures for surgery and pathology, a third level oncologic pathway was added and set up at a referral colorectal cancer center (RC). Lymph nodal (LN) harvesting, as a process indicator, and nodal positivity were adopted for an interim analysis. METHODS: The program was implemented by a series of audit meetings and a double type of multidisciplinary team (MDT): "horizontal" and "vertical." Three hundred and forty colorectal cancer (CRC) patients underwent surgery: 119 chose to be operated at the RC (Gr In), 65 were operated at 22 district hospitals (DH) (Gr Out), and 156 symptomatic not screened patients were operated at the RC (Gr Sym). RESULTS: Statistical analysis revealed differences between Gr In and Gr Out colon groups both for LN harvesting (median of 26 and 11, respectively, P = 0.0001), and for nodal positivity after the first screening round (34.78 and 19.45%, respectively, P = 0.0169). Results were all the more significant in a subset analysis on early T stage colon subgroups (In vs Out) both for LN harvesting (P < 0.0001) and nodal positivity (P < 0.0001). CONCLUSION: xSignificant differences between RC and DHs were found, particularly for early-stage CRCpatients. LN harvesting should be considered as a surrogate marker of quality assurance for at least screening hospitals for "minimum best" standard of care. This should lead to set up a third level in any CCSP.
Entities:
Keywords:
Colorectal cancer screening; Lymph nodal harvesting; Multidisciplinary team; Quality assurance; Referral centre; Third level surgery
Authors: J G Williams; R D Pullan; J Hill; P G Horgan; E Salmo; G N Buchanan; S Rasheed; S G McGee; N Haboubi Journal: Colorectal Dis Date: 2013-08 Impact factor: 3.788
Authors: Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; Mark S Talamonti; David P Winchester; Thomas R Russell; Clifford Y Ko Journal: J Natl Cancer Inst Date: 2008-09-09 Impact factor: 13.506
Authors: Paris P Tekkis; Jason J Smith; Alexander G Heriot; Ara W Darzi; Michael R Thompson; Jeffrey D Stamatakis Journal: Dis Colon Rectum Date: 2006-11 Impact factor: 4.585
Authors: Gea A Gooiker; Nikki E Kolfschoten; Esther Bastiaannet; Cornelis J H van de Velde; Eric H Eddes; Erwin van der Harst; Theo Wiggers; Frits R Rosendaal; Rob A E M Tollenaar; Michel W J M Wouters Journal: J Surg Oncol Date: 2013-09-20 Impact factor: 3.454
Authors: C J H van de Velde; P G Boelens; P J Tanis; E Espin; P Mroczkowski; P Naredi; L Pahlman; H Ortiz; H J Rutten; A J Breugom; J J Smith; A Wibe; T Wiggers; V Valentini Journal: Eur J Surg Oncol Date: 2013-11-08 Impact factor: 4.424
Authors: Cornelis J H van de Velde; Petra G Boelens; Josep M Borras; Jan-Willem Coebergh; Andres Cervantes; Lennart Blomqvist; Regina G H Beets-Tan; Colette B M van den Broek; Gina Brown; Eric Van Cutsem; Eloy Espin; Karin Haustermans; Bengt Glimelius; Lene H Iversen; J Han van Krieken; Corrie A M Marijnen; Geoffrey Henning; Jola Gore-Booth; Elisa Meldolesi; Pawel Mroczkowski; Iris Nagtegaal; Peter Naredi; Hector Ortiz; Lars Påhlman; Philip Quirke; Claus Rödel; Arnaud Roth; Harm Rutten; Hans J Schmoll; Jason J Smith; Pieter J Tanis; Claire Taylor; Arne Wibe; Theo Wiggers; Maria A Gambacorta; Cynthia Aristei; Vincenzo Valentini Journal: Eur J Cancer Date: 2013-10-31 Impact factor: 9.162
Authors: F Bianco; S De Franciscis; A Belli; A Falato; R Fusco; D F Altomare; A Amato; C R Asteria; A Avallone; G A Binda; L Boccia; P Buzzo; M Carvello; C Coco; P Delrio; P De Nardi; M Di Lena; A Failla; F La Torre; M La Torre; M Lemma; P Luffarelli; G Manca; I Maretto; F Marino; A Muratore; A Pascariello; S Pucciarelli; D Rega; V Ripetti; G Rizzo; A Serventi; A Spinelli; F Tatangelo; E D L Urso; G M Romano Journal: Tech Coloproctol Date: 2017-02-13 Impact factor: 3.781
Authors: Yara Backes; Sjoerd G Elias; Bibie S Bhoelan; John N Groen; Jeroen van Bergeijk; Tom C J Seerden; Hendrikus J M Pullens; Bernhard W M Spanier; Joost M J Geesing; Koen Kessels; Marjon Kerkhof; Peter D Siersema; Wouter H de Vos Tot Nederveen Cappel; Niels van Lelyveld; Frank H J Wolfhagen; Frank Ter Borg; G Johan A Offerhaus; Miangela M Lacle; Leon M G Moons Journal: BMC Med Date: 2017-07-14 Impact factor: 8.775